Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samuraciclib + fulvestrant in HR+ HER2- metastatic breast cancer
NCT05963984Phase 2Completed
- Sponsor
- Carrick Therapeutics
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of samuraciclib in breast cancer (3 arms), sponsored by Carrick Therapeutics. Primary endpoint: Clinical Benefit Response at 24 weeks. Started Nov 2023; status: completed.
02
Drugs
samuraciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05963984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963984.